XRAY

Rating neutralAI MemoPost-earnings T+3

DENTSPLY SIRONA

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 results and maintained outlook • 2026-08-07

Base target: $14 / p=50% prob

Biggest risk

Revenue declined 4.1%, Orthodontic and Implant Solutions remained sharply weak, and the stock fell 7.97% on August 7 despite maintained guidance. Retrieved analyst coverage shows mixed target actions, including an Evercore ISI cut from $15 to $13 and a Baird raise from $12 to $14; the timing of these actions relative to the print is not fully clear. Market data: https://stockanalysis.com/stocks/xray/history/ Analyst data: https://www.tipranks.com/stocks/xray/forecast

Invalidation

Break below $10 or thesis failure.

What would change my mind?

Adjusted EPS of $0.52 exceeded the $0.35 consensus estimate reported by Benzinga, adjusted EBITDA margin held at 21.3%, and management maintained full-year guidance. The Medline Sinclair expansion could support commercialization. Primary results source: [#8-K-2026-08-06]. Consensus source: https://www.benzinga.com/quote/XRAY/earnings

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-08

Base target

$14

p=50%

Bull target

$15

p=25%

Bear target

$10

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Orthodontic and implant weakness remains unresolved
Distributor expansion and connected-technology commercialization
Adjusted EPS of $0.52 exceeded the $0.35 consensus estimate reported by Benzinga, adjusted EBITDA margin held at 21.3%, and management maintained full-year guidance.

BearKey bullets

Analyst target actions are mixed and their precise post-print timing is not fully available; complete estimate revisions, options, short-interest, and social coverage are unavailable.
Maintained guidance requires a meaningful second-half recovery without an upward revision.
Operating cash-flow improvement included approximately $44 million of tariff refunds, which may not recur.

WatchKey bullets

Q2 2026 results and maintained outlook

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $14 (p=50%)

Target spread vs base: +9% / -31%

Scenario probabilities

Bull Target: $15 (p=25%)Base Target: $14 (p=50%)Bear Target: $10 (p=25%)

Commentary

The post-earnings signal is mixed but the immediate market reaction was decisively negative: XRAY closed at $12.12 on August 7, down 7.97% from the prior close. The company reported stable adjusted EPS, said results were in line with expectations, and maintained guidance, but declining revenue and pronounced Orthodontic and Implant Solutions weakness leave forward visibility limited. Analyst target actions are mixed and not fully attributable to the post-print period; this remains a monitoring-style thesis.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Orthodontic and implant weakness remains unresolved
Distributor expansion and connected-technology commercialization

Scenarios

Bull Target (Scenario probability)

$15 / p=25% prob

Base Target (Scenario probability)

$14 / p=50% prob

Bear Target (Scenario probability)

$10 / p=25% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.30

Social Sentiment (7d)

Events

Other notable items detected

EVENT2026-08-07
Q2 2026 results and maintained outlook
The company reported Q2 net sales of $898 million, adjusted EPS of $0.52, and adjusted EBITDA margin of 21.3%. Management said results were in line with expectations and maintained 2026 sales guidance of $3.5-$3.6 billion and adjusted EPS guidance of $1.40-$1.50. [#8-K-2026-08-06]
Prob 100.00% • Move -8.00% • Priced-in 100.00%

Short-term Catalysts

Next few weeks

Orthodontic and implant weakness remains unresolved
2026-12-31
Orthodontic and Implant Solutions revenue fell 14.9% reported and 15.6% in constant currency in Q2, while total constant-currency sales declined 6.3%. Failure to stabilize this segment could weaken the recovery profile by year-end. [#8-K-2026-08-06]
Prob 65% • Move -12% • Priced-in 55%

Long-term Catalysts

Months to a year

Distributor expansion and connected-technology commercialization
2026-12-31
The expanded Medline Sinclair partnership broadens access to the Connected Technology Solutions portfolio across Canada, supporting the Return-to-Growth plan. Adoption and margin benefits remain early-stage and unproven. [#8-K-2026-08-06]
Prob 45% • Move 10% • Priced-in 35%

Risks

Analyst target actions are mixed and their precise post-print timing is not fully available; complete estimate revisions, options, short-interest, and social coverage are unavailable.
Maintained guidance requires a meaningful second-half recovery without an upward revision.
Operating cash-flow improvement included approximately $44 million of tariff refunds, which may not recur.
Orthodontic and Implant Solutions declined 14.9% reported and 15.6% in constant currency.
Q2 total sales declined 4.1% reported and 6.3% in constant currency.
The August 7 close fell 7.97%, indicating negative market interpretation despite stable adjusted EPS and guidance. Source: https://stockanalysis.com/stocks/xray/history/

Peers

Symbol	Summary
ABT	Large diversified medtech benchmark; useful for sector context but materially larger and less directly comparable to XRAY.
BSX	Large medical-device benchmark with greater scale and different procedure exposure; broad rather than direct peer.
EW	Large medtech benchmark with different device categories and growth profile; valuation comparison is loose.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

ABT

Large diversified medtech benchmark; useful for sector context but materially larger and less directly comparable to XRAY.

BSX

Large medical-device benchmark with greater scale and different procedure exposure; broad rather than direct peer.

Large medtech benchmark with different device categories and growth profile; valuation comparison is loose.